Bio-Path (BPTH) provided an update from the company’s ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of ...

Researchers determined discontinuing BTK inhibitors appears to be more common than discontinuing venetoclax plus obinutuzumab for older patients with CLL.

Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

Venetoclax, a selective Bcl-2 inhibitor, has proven effective in chronic lymphocytic leukemia (CLL), but genetic mutations or ...

With the second week of the BCL Round of 16 in the books already, entering the February break for domestic cups and ...